# A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct05765812/  
OnCo record `nct05765812` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Debiopharm International SA, now recruiting.

## Summary

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT05765812 by Debiopharm International SA, with 116 participants planned, started 2023-05-15 and due to reach its primary completion in 2028-09. Interventions recorded: Debio 0123, Temozolomide and Radiotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05765812
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Sponsor: Debiopharm International SA
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT05765812: https://clinicaltrials.gov/study/NCT05765812

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct05765812.json